Idiopathic Pulmonary Fibrosis Market to Register Incremental Growth During the Forecast Period 2032, Asserts DelveInsight | Key Companies – Roche, FibroGen, MediciNova, Novartis, Calliditas, Celgene

Idiopathic Pulmonary Fibrosis Market to Register Incremental Growth During the Forecast Period 2032, Asserts DelveInsight | Key Companies - Roche, FibroGen, MediciNova, Novartis, Calliditas, Celgene

“Delveinsight Business Research LLP”
The Idiopathic Pulmonary Fibrosis market is expected to increase in the upcoming years owing to the rising prevalent population of Idiopathic Pulmonary Fibrosis (IPF) patients in the 7MM, the launch of emerging therapies, and the active participation of the key pharma and biotech companies in the therapeutics domain.

DelveInsight’s “Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Idiopathic Pulmonary Fibrosis Market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).

The Idiopathic Pulmonary Fibrosis market report covers emerging drugs, current treatment practices, market share of the individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, market drivers & barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Idiopathic Pulmonary Fibrosis: An Overview

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive form of interstitial lung disease (ILD), characterized by fibrosis and worsening lung function, that primarily occurs in those 50 years and older. Various causes, including genetic susceptibility, environmental risk factors, and exposures, have been suggested in the literature. However, as the symptoms of IPF are similar to other lung diseases, like asthma and chronic obstructive lung disease (COPD), this results in misdiagnosis of initial presentation.

IPF affects approximately 132,000 people in the US, with about 50,000 new diagnoses yearly. 

Idiopathic Pulmonary Fibrosis Market Key Facts

  • As per DelveInsight, the total prevalent population of Idiopathic Pulmonary Fibrosis (IPF) in the 7MM is expected to rise during the study period. Estimates show the highest prevalent population of Idiopathic Pulmonary Fibrosis (IPF) is in the United States followed by the UK.

  • According to DelveInsight’s analysis, it has been observed that Moderate Idiopathic Pulmonary Fibrosis (IPF) cases are more prominent in comparison to Mild and Severe cases across 7 MM.

  • Males have a higher prevalence of Idiopathic Pulmonary Fibrosis as compared to females.

  • Among the European 5 countries, the United Kingdom had the highest prevalent population of Idiopathic Pulmonary Fibrosis (IPF), followed by Italy and Germany. On the other hand, Spain had the lowest prevalent population of IPF.

  • The lowest prevalent population of Idiopathic Pulmonary Fibrosis (IPF) was recorded in Japan.

Idiopathic Pulmonary Fibrosis Market

The Idiopathic Pulmonary Fibrosis market is expected to increase during the forecast period owing to the increasing prevalent population of Idiopathic Pulmonary Fibrosis (IPF) patients in the 7MM.

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Idiopathic Pulmonary Fibrosis market size by analyzing the impact of current and emerging therapies in the market. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies.

The report gives complete detail of the Idiopathic Pulmonary Fibrosis market trend for each marketed drug and late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, mechanism of action (MoA), and competition with other therapies, brand value, and their impact on the market.

Idiopathic Pulmonary Fibrosis Epidemiology

Understanding the complex pathogenesis of Idiopathic Pulmonary Fibrosis has evolved significantly over the past 2 decades. It is now generally agreed that the pathogenesis of IPF is related to epithelial injury from endogenous or exogenous events, which results in widespread fibrosis, which replaces the normal lung parenchyma. Clinically, these changes can result in decreased oxygenation, respiratory failure, and eventually death.

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of diagnosed patient pool and future trends.

Idiopathic Pulmonary Fibrosis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Idiopathic Pulmonary Fibrosis market or expected to get launched during the study period. The analysis covers Idiopathic Pulmonary Fibrosis market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Idiopathic Pulmonary Fibrosis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Request for Sample PDF Report –

Idiopathic Pulmonary Fibrosis Therapeutics Analysis

There are approx. 80+ key companies which are developing therapies for Idiopathic Pulmonary Fibrosis. The companies with Idiopathic Pulmonary Fibrosis drug candidates in the most advanced stage, i.e., phase III, include Hoffmann-La Roche.

The available therapeutics treatment options in the Idiopathic Pulmonary Fibrosis (IPF) Landscape aims to slow the disease progression and not stop the disease to improve survival benefits. To overcome the drawbacks of the treatment many companies are working robustly to identify the cause of disease and targeted therapy.

Some of the key companies in the Idiopathic Pulmonary Fibrosis Market include:

Roche, FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Syndax Pharmaceuticals, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, Astra Zeneca, Regend Therapeutics, Lung Therapeutics, Bridge Biotherapeutics, AstraZeneca, Kinarus AG Insmed, and several others

Idiopathic Pulmonary Fibrosis therapies covered in the report include:

  • Pamrevlumab

  • KD025

  • PRM-151

  • GLPG1690

  • Tipelukast

And many more. 

Get More Detailed Insights Into the Emerging Therapies & Key Companies –

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Idiopathic Pulmonary Fibrosis Competitive Intelligence Analysis

4. Idiopathic Pulmonary Fibrosis Market Overview at a Glance

5. Idiopathic Pulmonary Fibrosis Disease Background and Overview

6. Idiopathic Pulmonary Fibrosis Patient Journey

7. Idiopathic Pulmonary Fibrosis Epidemiology and Patient Population

8. Idiopathic Pulmonary Fibrosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Idiopathic Pulmonary Fibrosis Unmet Needs

10. Key Endpoints of Idiopathic Pulmonary Fibrosis Treatment

11. Idiopathic Pulmonary Fibrosis Marketed Products

12. Idiopathic Pulmonary Fibrosis Emerging Therapies

13. Idiopathic Pulmonary Fibrosis Seven Major Market Analysis

14. Attribute Analysis

15. Idiopathic Pulmonary Fibrosis Market Outlook (7 major markets)

16. Idiopathic Pulmonary Fibrosis Access and Reimbursement Overview

17. KOL Views on the Idiopathic Pulmonary Fibrosis Market.

18. Idiopathic Pulmonary Fibrosis Market Drivers

19. Idiopathic Pulmonary Fibrosis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report –

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.


Other Latest Healthcare Reports by DelveInsight

Secondary Myelofibrosis Market
“Secondary Myelofibrosis Market” research report provides a detailed overview of the disease, an in-depth understanding of the historical and forecasted epidemiology, market size, share, trends, ongoing developments, as well as the key companies and the emerging therapies in the Secondary Myelofibrosis Therapeutics Market. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Anuj Rawat
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States